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OBJECTIVE — Diabetes and heart failure commonly coexist, and prior studies have sug-
gestedbetteroutcomeswithmetforminthanotherantidiabeticagents.Wedesignedthisstudyto
determine whether this association reﬂects a beneﬁcial effect of metformin or a harmful effect of
other agents.
RESEARCH DESIGN AND METHODS — We performed a case-control study nested
within the U.K. General Practice Research Database cohort in which diagnoses were assigned by
each patient’s primary care physician. Case subjects were patients 35 years or older, newly
diagnosedwithbothheartfailureanddiabetesafterJanuary1988,andwhodiedpriortoOctober
2007.Controlsubjectswerematchedtocasesubjectsbasedonage,sex,clinicsite,calendaryear,
and duration of follow-up. Analyses were adjusted for comorbidities, A1C, renal function, and
BMI.
RESULTS — The duration of concurrent diabetes and heart failure was 2.8 years (SD 2.6) in
our 1,633 case subjects and 1,633 control subjects (mean age 78 years, 53% male). Compared
with patients who were not exposed to antidiabetic drugs, the current use of metformin mono-
therapy(adjustedoddsratio0.65[0.48–0.87])ormetforminwithorwithoutotheragents(0.72
[0.59–0.90]) was associated with lower mortality; however, use of other antidiabetic drugs or
insulin was not associated with all-cause mortality. Conversely, the use of ACE inhibitors/
angiotensin receptor blockers (0.55 [0.45–0.68]) and -blockers (0.76 [0.61–0.95]) were as-
sociated with reduced mortality.
CONCLUSIONS — Our results conﬁrm the beneﬁts of trial-proven anti-failure therapies in
patients with diabetes and support the use of metformin-based strategies to lower glucose.
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D
iabetesisacommoncomorbidityin
patients with heart failure, but the
choice of treatment for type 2 dia-
betes in individuals with heart failure re-
mains controversial (1). Patients with
heartfailurehavebeengenerallyexcluded
from the trials of glucose-lowering thera-
pies, and the safety of antidiabetic agents
in heart failure patients remains unclear
(1). In the absence of randomized trial
evidence in patients with both diabetes
and heart failure (the only placebo-
controlled trial conducted in heart failure
was small [n  224] and had insufﬁcient
clinical events to draw any ﬁrm conclu-
sions) (2), one must rely on observational
evidence to judge the safety of antidia-
betic drugs in patients with concomitant
heart failure.
A number of observational studies
have reported prognostic differences be-
tween various antidiabetic agents when
used in patients with concomitant heart
failure (3,4). However, all of these studies
involved comparisons between patients
taking active drug therapy. Without a “no
drug” comparison group it is impossible
to deﬁnitively say whether the observed
inter-drug differences were because one
of the drug classes was harmful or
whether the comparator was beneﬁcial.
Moreover, all of these observational stud-
ies lacked data on potential confounders
such as glycemic control, weight, and
other laboratory parameters known to be
prognostic in heart failure, raising the
possibility that any reported differences
between drug classes were actually due to
residual confounding.
The U.K. General Practice Research
Database (GPRD) is a well-validated co-
hortwithhigh-qualityinformationonco-
morbidities and therapy that is often used
for studies of beneﬁts and harms related
to prescription drugs (5). It was impor-
tant for our purposes that the GPRD da-
tabase also contains laboratory data, and
the diagnoses are assigned by clinicians
(ratherthanrelyingonprescriptionorad-
ministrativeclaimsdatatodeﬁneapatient
as having diabetes or heart failure). This
permits us to include patients who were
not exposed to antidiabetic drugs in our
analyses. Therefore, we designed this
study to examine outcomes in patients
with diabetes and heart failure and to de-
termine whether outcomes were associ-
ated with antidiabetic drug therapy.
RESEARCH DESIGN AND
METHODS— We conducted a case-
control study nested within the prospec-
tive U.K. GPRD cohort, which collects
data from over 450 general practitioners
in the U.K. The database includes infor-
mation on patient demographics, physio-
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pressure, BMI, renal function, choles-
terol), diagnoses, and out-patient pre-
scription medications. Clinical diagnoses
areassignedand/orconﬁrmedbyeachpa-
tient’s primary care physician and are re-
corded using the Oxford Medical
Information System classiﬁcation and
Read Clinical Terms. Prescription medi-
cations are coded according to the GPRD
product code (see the online appendix,
available at http://care.diabetesjournals.
org/cgi/content/full/dc09-2227/DC1).
Cardiovascular medication data were ex-
amined for the 90 days prior to index
date;clinicalcomorbiditieswerecodedas
present if they were diagnosed at any
point between entry into the GPRD and
the index date. In order to reduce error in
the code selection for each diagnosis,
code searches were carried out indepen-
dently by two researchers and the results
subsequently were cross-checked by a
third.
We chose a nested case–control de-
sign to reduce confounding by indication
and to account for time varying changes
in patient characteristics and antidiabetic
drug exposures. Prior studies have con-
ﬁrmed that the nested case–control de-
sign we employed provides unbiased
estimates of associations similar to those
obtained from traditional cohort time-to-
event analyses but with greater efﬁciency
(5,6).
Study sample
Our cohort consisted of all patients older
than age 35 with both newly diagnosed
type 2 diabetes and newly diagnosed
heart failure between January 1988 and
October2007.Weexcludedpatientswith
a prevalent diagnosis of diabetes or heart
failure before 1988 and those with type 1
diabetes, gestational, or drug-induced di-
abetes. We restricted our cohort to only
those patients who had at least 1 year of
data prior to their index date. The accu-
racy of the U.K. GPRD clinical diagnoses
of diabetes and heart failure have previ-
ously been validated by chart audit (7).
All subjects were followed from the date
they were diagnosed with diabetes or
heart failure until death, termination of
their involvement in the GPRD (“trans-
ferred out of practice”), or October 31,
2007.
We selected case subjects (patients
within the cohort with diabetes and heart
failure who had died) and 1:1 matched
them to control subjects from our cohort
based on age (5 years), sex, general
practice, calendar year, and years of fol-
low-up within the GPRD (Table 1).
To be eligible as a control subject,
subjects had to have diabetes and heart
failureandbealiveontheindexdate(i.e.,
the date their matched case died on). We
choseall-causemortality(ratherthancar-
diac or heart failure mortality) as we felt
that this would best capture both the
safety and the beneﬁts of antidiabetic
therapies.
Exposure deﬁnitions
For each drug examined, we deﬁned cur-
rent use as at least one prescription re-
corded in the 90 days prior to the index
date (death for case subjects or analogous
date for control subjects). We classiﬁed
antidiabetic drug exposure into seven
mutually exclusive categories: no antidia-
betic drug therapy, sulfonylurea mono-
therapy, metformin monotherapy,
thiazolidinedione monotherapy, insulin
monotherapy, combination therapy with
insulin, and combination oral therapy
without insulin.
To evaluate the robustness of our ob-
servations, we evaluated “any use” of an-
tidiabetic drugs in a sensitivity analysis
(eitherasmonotherapyorincombination
with other agents) in the 90 days prior to
theindexdateinourmultivariatemodels.
In other sensitivity analyses, we adjusted
for duration of diabetes, duration of heart
failure, and whether the patient devel-
oped diabetes or heart failure ﬁrst. Fi-
nally, we also examined drug use in the 6
months and 12 months prior to the index
date.
Statistical analyses
Conditional logistic regression was used
to estimate crude and adjusted ORs for
the seven drug exposure categories de-
scribed above. In addition to the matched
variables (age, sex, general practice, years
of follow-up within the GPRD), we ad-
justed for numerous potential confound-
ing variables (Table 2). We did not have
access to ejection fraction or electrocar-
diogram data. All analyses were con-
ducted using SAS version 9.2 (SAS
Institute, Cary, NC), and statistical signif-
icance was accepted at a P value of 0.05.
The protocol was approved by the GPRD
Independent Scientiﬁc Advisory
Committee.
RESULTS— Of the 8,404 patients in
the U.K. GPRD who were newly diag-
nosedwithbothdiabetesandheartfailure
between 1988 and 2007, we were able to
match 1,633 patients who died with
1,633 control subjects. The mean time
livingwithbothdiabetesandheartfailure
was 2.8 years and was similar in case and
control subjects (Table 1). Diabetes was
diagnosed ﬁrst in 54% of case subjects
and 41% of control subjects, and the
meantimeuntiltheywerediagnosedwith
heart failure was 3.9  3.3 and 3.5  2.9
years,respectively.Heartfailurewasdiag-
nosed ﬁrst in 44% of case subjects and
58% of control subjects, and the mean
time until they were diagnosed with dia-
betes was 3.1  2.8 and 3.2  2.9 years,
respectively. Diabetes and heart failure
were diagnosed at the same visit in 2% of
case subjects and 1% of control subjects.
Baseline characteristics
The mean age of our study sample was 78
years (SD 8) at the index date, 1,738 were
male (53%), and the average time fol-
lowed within the GPRD was 11 years (SD
4). Case and control subjects were well-
matchedwithrespecttoage,sex,andtime
within the GPRD (Table 1). As expected,
case subjects (i.e., patients who died) ex-
hibited signiﬁcantly higher rates of co-
morbidities and abnormal laboratory
values than control subjects, and they
were signiﬁcantly less likely to receive
various anti-failure medications (Table
1). In unadjusted analyses, hypotension,
elevated serum creatinine, anemia,
chronic obstructive pulmonary disease,
cancer, dementia, cerebrovascular dis-
ease, and prior myocardial infarction
were all poor prognostic factors in pa-
tients with diabetes and heart failure; on
the other hand, elevated BMI was associ-
ated with lower mortality risk.
Cardiovascular therapy
Six hundred and four (18%) subjects re-
ceived both an ACE inhibitor/angiotensin
receptor blocker (ARB) and a -blocker;
271 (12%) of those with atherosclerotic
disease (i.e., prior myocardial infarction,
revascularization, angina, cerebrovascu-
lar, or peripheral vascular disease) received
anACEinhibitor/ARB,a-blocker,astatin,
and aspirin. The use of ACE inhibitors,
ARBs, -blockers, aspirin, digoxin, and
statins were all independently associated
with reduced mortality risk in patients with
concomitant heart disease and diabetes
(Table 2).
Diabetes therapy
A substantial minority of patients were
not exposed to antidiabetic drugs in the
90dayspriortotheindexdate(n1,306
Metformin in heart failure
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controlled with diet and lifestyle as 1,102
(84%) had not received any antidiabetic
drugs in the 12 months preceding their
index date (we did not examine medica-
tionusemorethan12monthspriortothe
index date). Sulfonylurea monotherapy
was the most common antidiabetic drug
regimen among case and control subjects
(n  753 [23%]), followed by combina-
tion oral therapies without insulin (n 
470 [14%]), and metformin mono-
therapy (n  376, [12%]).
All-cause mortality
In unadjusted analyses, when compared
with patients not exposed to antidiabetic
therapy, current users of sulfonylurea
monotherapy, metformin monotherapy,
or combination therapy all exhibited
lower mortality risk (Table 2). However,
only current use of metformin mono-
therapywasassociatedwithlowermortal-
ity risk after adjustment for covariates
(Table 2) (adjusted OR 0.65 [0.48–
0.87]). The association between current
metformin monotherapy and lower mor-
tality was maintained even if duration of
diabetes and duration of heart failure
were included in the Table 2 multivariate
Table 1—Characteristics of case patients and matched control patients
Control subjects
(n  1,633)
Case subjects
(n  1,633)
Crude OR
(95% CI)
At time of index date:
Years in GPRD (mean, SD) 11.2  4.0 11.3  3.9 Matching variable
Time living with both diabetes and HF (mean, SD) 2.9  2.6 2.7  2.6 0.96 (0.93–0.98)
Mean age  SD 77.8  7.8 78.2  8.0 Matching variable
Male, n (%) 869 (53.2) 869 (53.2) Matching variable
Lab/physical exam values at the time HF and
diabetes concomitant diagnoses made:
Systolic BP 120 mmHg 184 (11.3) 250 (15.3) 1.43 (1.16–1.75)
BMI 25 286 (17.5) 372 (22.8) reference
25–29.9 554 (33.9) 544 (33.3) 0.76 (0.63–0.93)
30 605 (37.1) 460 (28.2) 0.56 (0.46–0.69)
Hemoglobin 120 g/l 271 (16.6) 351 (21.5) 1.75 (1.45–2.12)
Serum creatinine, mol/l reference
132 1,182 (72.4) 1,001 (61.3)
133–221 248 (15.2) 270 (16.5) 1.30 (1.07–1.58)
222 26 (1.6) 48 (2.9) 2.20 (1.35–3.60)
A1C 6 226 (13.8) 247 (15.1) reference
6–6.9 530 (32.5) 453 (27.7) 0.74 (0.59–0.92)
7–7.9 370 (22.7) 292 (17.9) 0.67 (0.52–0.86)
8 320 (19.6) 304 (18.6) 0.84 (0.66–1.08)
Comorbidities:
Hypertension 929 (56.9) 857 (52.5) 0.82 (0.71–0.95)
Prior myocardial infarct or coronary
revascularization 497 (30.4) 625 (38.3) 1.44 (1.23–1.67)
Valvular heart disease 157 (9.6) 189 (11.6) 1.25 (0.99–1.58)
Angina 679 (41.6) 672 (41.2) 0.98 (0.85–1.13)
Atrial ﬁbrillation 588 (36.0) 589 (36.1) 1.00 (0.87–1.16)
Dyslipidemia 332 (20.3) 287 (17.6) 0.80 (0.65–0.97)
Chronic obstructive lung disease 276 (16.9) 366 (22.4) 1.44 (1.20–1.72)
Cerebrovascular disease 381 (23.3) 488 (29.9) 1.43 (1.21–1.67)
Current smoker 185 (11.3) 202 (12.4) 1.11 (0.88–1.40)
Peripheral vascular disease 260 (15.9) 245 (15.0) 0.93 (0.77–1.13)
Cancer 128 (7.8) 259 (15.9) 2.21 (1.76–2.78)
Dementia 45 (2.8) 69 (4.2) 1.57 (1.07–2.31)
Peptic ulcer disease 147 (9.0) 169 (10.4) 1.17 (0.93–1.49)
Medications within 90 days of index date:
ACE inhibitor 994 (60.9) 778 (47.6) 0.57 (0.49–0.65)
ARB 214 (13.1) 116 (7.1) 0.47 (0.36–0.61)
Aspirin 878 (53.8) 685 (42.0) 0.61 (0.53–0.70)
Digoxin 539 (33.0) 463 (28.4) 0.80 (0.69–0.93)
-blocker 442 (27.1) 313 (19.2) 0.61 (0.52–0.73)
Statin 760 (46.5) 571 (35.0) 0.47 (0.39–0.56)
Spironolactone 194 (11.9) 263 (16.1) 1.44 (1.17–1.77)
Data are frequency (%) unless otherwise indicated. For lab/physical exam values, data was missing on systolic blood pressure (BP) for 43 patients, BMI for 445
patients, hemoglobin for 906 patients, creatinine for 491 patients, and A1C for 523 patients. HF, heart failure.
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merular ﬁltration rate was included in the
model as a continuous rather than cate-
gorical variable (0.68 [0.49–0.93]); and
even if we adjusted for whether or not
diabetes was diagnosed ﬁrst (0.65 [0.48–
0.88]). We did not ﬁnd any association
between current use of other antidiabetic
therapies (including insulin) and all-
cause mortality, although few subjects
were current users of thiazolidinedione
monotherapy resulting in risk estimates
with very wide CIs.
When we examined the outcomes for
“any use” of drugs, whether or not they
were dispensed in combination or as
monotherapy, again only metformin (ad-
justed OR 0.72 [0.59–0.90], P  0.003)
wassigniﬁcantlyassociatedwithall-cause
mortality. No association was observed
for any of the other antidiabetic drug cat-
egories (P  0.2 for all comparisons) (Ta-
ble 2). When we examined longer-term
use of metformin monotherapy (i.e.,
those patients prescribed metformin
monotherapy within the last 6 months
and the last 12 months before the index
date), the number of individuals available
for analysis was fewer (since fewer pa-
tients were on monotherapy for 6 or 12
Table 2—Use of antidiabetic drugs and risk of mortality
Control subjects
n  1,633
Case subjects
n  1,633
Unadjusted
OR (95% CI)
Adjusted
OR (95%CI)
Diabetes treatment in the 90 days prior to index date:
No antidiabetic drugs 573 (35) 733 (45) Reference category
Sulphonylurea monotherapy 391 (24) 362 (22) 0.73 (0.61–0.88) 0.84 (0.67–1.06)
Metformin monotherapy 221 (14) 155 (9) 0.54 (0.42–0.68) 0.65 (0.48–0.87)
Thiazolidinedione monotherapy 4 (0.2) 5 (0.3) 0.93 (0.24–3.53) 1.08 (0.23–5.07)
Insulin monotherapy 89 (5) 141 (9) 1.19 (0.88–1.60) 1.24 (0.85–1.80)
Combination therapy with insulin 76 (5) 46 (3) 0.47 (0.32–0.70) 0.72 (0.44–1.17)
Combination oral therapy without insulin 279 (17) 191 (12) 0.52 (0.42–0.65) 0.74 (0.56–0.99)
Any use of diabetic drugs in the 90 days prior to
index date (as monotherapy or as part of
combination therapy):
Any sulphonylurea 674 (41) 566 (35) 0.75 (0.65–0.87) 0.90 (0.75–1.08)
Any metformin 529 (32) 349 (21) 0.55 (0.46–0.65) 0.72 (0.59–0.90)
Any thiazolidinedione 59 (4) 40 (2) 0.64 (0.42–0.99) 0.92 (0.54–1.55)
Any insulin 165 (10) 187 (11) 1.16 (0.92–1.45) 1.11 (0.83–1.50)
Covariates included in the multivariate models:
Age (adjusted OR per year) 1.08 (1.03–1.13)
Systolic BP (adjusted OR for 120 mmHg) 1.89 (1.48–2.40)
Diastolic BP (adjusted OR for 90 mmHg) 0.96 (0.71–1.31)
BMI (adjusted OR for 30) 0.67 (0.52–0.86)
Hemoglobin (adjusted OR for 120 g/l) 1.76 (1.41–2.19)
Hemoglobin A1C (adjusted OR for 8) 1.06 (0.77–1.46)
GFR (adjusted OR for 30 ml   min
1   kg
1) 2.04 (1.44–2.88)
Hypertension 1.05 (0.87–1.26)
Prior myocardial infarct or coronary
revascularization 1.83 (1.49–2.25)
Valvular heart disease 1.22 (0.91–1.63)
Angina 1.02 (0.84–1.24)
Atrial ﬁbrillation 1.08 (0.87–1.34)
Dyslipidemia 0.95 (0.73–1.22)
Chronic obstructive lung disease 1.17 (0.93–1.48)
Cerebrovascular disease 1.56 (1.27–1.90)
Smoker (current or former) 0.84 (0.69–1.04)
Peripheral vascular disease 1.01 (0.79–1.28)
Cancer 1.94 (1.47–2.55)
Dementia 1.25 (0.77–2.01)
Peptic ulcer disease 1.01 (0.75–1.36)
Medication use within 90 days of index date:
ACE inhibitor/ARB 0.55 (0.45–0.68)
Aspirin 0.66 (0.55–0.80)
Digoxin 0.74 (0.59–0.93)
-blocker 0.76 (0.61–0.95)
Statin 0.59 (0.46–0.75)
Spironolactone 1.20 (0.93–1.55)
Data are n (%) unless otherwise indicated. BP, blood pressure.
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point estimates of risk were nearly identi-
cal (adjusted OR 0.76 for 6 months and
0.80 for 12 months), the 95% CIs were
wider (0.56–1.03 for 6 months and
0.59–1.09 for 12 months).
CONCLUSIONS — Wehavedemon-
strated that, compared with those indi-
vidualsnotexposedtoantidiabeticdrugs,
metformin use is associated with a lower
mortality risk than other antidiabetic
therapies even after adjustment for other
potential prognostic factors including
glycemic control, renal function, BMI,
and blood pressure. This is consistent
with prior studies demonstrating that in
patients with heart failure, metformin us-
erswereatlowermortalityriskthanusers
of other antidiabetic therapies (3,4). By
including heart failure patients with dia-
betes who were not exposed to antidia-
betic drugs (a subgroup previously
demonstrated to have better glycemic
control and less of a burden of macrovas-
cular complications than those treated
with antidiabetic therapy in the U.K.) (8),
we have advanced the evidence base as
our results suggest that the apparent ben-
eﬁt of metformin over other antidiabetic
agents is due to reduced mortality risk
withmetforminratherthanharmwiththe
other agents. While residual confounding
by indication is always a possibility in an
observational study, at the very least our
results suggest that the use of metformin
in outpatients with heart failure and dia-
betes is not harmful.
While the 40% prevalence of patients
not exposed to antidiabetic drugs in our
study sample may seem high, it is not in-
consistent with prior studies of individu-
als with type 2 diabetes in U.K. general
practice. For example, a cross-sectional
study of 253,618 patients from 42 U.K.
general practices documented that 31%
of all patients with type 2 diabetes (me-
dianage59years)werebeingtreatedwith
diet and lifestyle rather than medications
(8).Asourstudysubjectswerenearlytwo
decades older and had a condition (heart
failure)thathasapoorprognosisandusu-
ally necessitates treatment with multiple
drugs, it is not unreasonable to speculate
that clinicians may have been reluctant to
contributefurthertothepolypharmacyin
these patients by adding glucose-
lowering agents. In addition, some may
question the apparent low frequency of
concomitant heart failure and diabetes in
the U.K. GPRD. However, the 8,404 indi-
viduals we identiﬁed with both condi-
tions newly diagnosed between 1988 and
2007 is consistent with another recent
analysis from the U.K. GPRD that re-
ported 6,900 incident cases of heart fail-
ure in U.K. GPRD enrollees with diabetes
between 1990 and 2005 (9).
Althoughthemechanismofactionfor
metformin is not completely understood,
it improves insulin sensitivity. This has
important implications because insulin
resistance is a negative prognostic factor
in patients with heart failure and is asso-
ciated with more advanced symptoms
(10,11). Attention is now focusing on in-
sulin resistance as a potential novel target
for therapy in patients with heart failure
(12,13), and randomized trials are
needed to deﬁnitively establish whether
insulin-sensitizing agents (such as met-
formin) reduce morbidity and mortality
in patients with heart failure and insulin
resistance (with or without overt
diabetes).
While we did not ﬁnd a signiﬁcant
associationbetweenbaselineorfollow-up
A1C levels and mortality in our study
subjects, we did adjust for this marker of
glycemiccontrolinouranalysesgiventhe
conﬂicting literature on this topic (14–
16). While the issue of optimal glycemic
targets in all patients with type 2 diabetes
(not just those with heart failure) remains
a topic of great debate (17), our case-
control design does not permit us to ana-
lyze this relationship.
Our demonstration of reduced mor-
tality risk in diabetic heart failure patients
who are current users of ACE inhibitors
and -blockers conﬁrms that these anti-
failure agents proven efﬁcacious in trials
are effective when deployed in usual clin-
ical practice in diabetic individuals
(18,19). Nevertheless, only 18% of our
study patients were receiving both an
ACE inhibitor/ARB and a -blocker, and
only 12% of those with heart failure, dia-
betes, and overt atherosclerotic disease
were receiving ACE inhibitor/ARB,
-blocker, statin, and aspirin. The unde-
ruse of proven efﬁcacious therapies in pa-
tientswithdiabetesisacommonthemein
healthservicesresearchanddoesresultin
adverse patient outcomes (20).
Although our study was conducted
using data collected prospectively within
the U.K. GPRD (and thus is free from re-
call bias), there are some limitations. We
relied on physician diagnoses or docu-
mentation of heart failure, comorbidities,
and risk factors, and we do not have in-
dependent conﬁrmation of diagnoses or
data on left ventricular ejection fraction.
However, previous studies have validated
the accuracy of these diagnoses in the
GPRD(7).Moreover,thefactthatmedian
survival with both diabetes and heart fail-
ure in our cohort was only 2.8 years sug-
gests that the patients likely did have
heart failure. While there may be a selec-
tion bias in the choice of antidiabetic
agents (e.g., “lower-risk” patients being
selected for metformin treatment), we
have adjusted for clinical and medication
covariates associated with mortality in
our analyses, and we used those diabetic
individuals not exposed to antidiabetic
drugs (who are presumably the lowest
risk group) as the referent category in our
multivariate analyses. While duration of
diabetes may be associated with current
antidiabetic therapy (e.g. metformin be-
ing used in patients earlier in their course
of diabetes), we did adjust for duration of
bothdiabetesandheartfailureinoursen-
sitivity analyses and the associations we
reported were preserved. A recent analy-
sis from a single U.S. center with detailed
information on ejection fraction, Brain
NatriureticPeptide(BNP),andfunctional
capacity also found that users of met-
formin exhibited better outcomes than
users of other antidiabetic therapies, al-
though there were too few events to
achieve statistical signiﬁcance after ad-
justment (adjusted HR 0.63, 95% CI
0.21–1.89) (4). Our analysis focused on
current drug therapies taken by patients
at their index date and although it
provides reassurance that there is no
short-term adverse effect with starting
metformininpatientswithheartfailure,it
does not inform debates about the long-
term effects of these therapies or the im-
pact of switching between drug classes.
However, our study design removed the
potential for immortal time bias to distort
our results, ensured that underascertain-
ment of early events related to drug expo-
sures did not occur, and effectively dealt
with attrition of susceptibles and other
patient–related factors associated with
poor adherence to antidiabetic treatment
that can impact analyses using longer
time frames to deﬁne drug exposure. Fi-
nally, this is an observational study and,
as such, the potential for unmeasured
confounders to have impacted our ﬁnd-
ings is always present.
In conclusion, while metformin has
similar or superior effects on glycemic
control,fastinglipids,andweightasother
antidiabetic agents (21), data on clinical
outcomes with the use of different antidi-
abetic agents are sparse and inconclusive
MacDonald and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 6, JUNE 2010 1217(22), especially in patients with heart fail-
ure. Our ﬁndings are consistent with ob-
servational studies conducted in the U.S.
andCanadademonstratingthatheartfail-
ure patients using metformin (compared
with users of other antidiabetic agents)
have better outcomes (3). However, our
study extends this evidence base by illus-
trating that metformin users exhibited
lower mortality risk than a group of age-
or sex-matched diabetic individuals not
exposed to antidiabetic drugs, and this
beneﬁt was independent of glycemic con-
trol,BMI,andotherprognosticfactorsnot
available in previous studies. Until ran-
domized trial evidence becomes avail-
able, we believe our study and the extant
publishedliterature(3)supporttheuseof
metformin-based strategies for glucose
lowering in patients with diabetes and
heart failure.
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